SCHEMBL2397191

SCHEMBL2397191

Cc1nc(Nc2cnccn2)sc1-c1cccc(S(=O)(=O)Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.45
ADORA3 P0DMS8 3/20 0.43
ADORA2A P29274 3/20 0.43
ADORA1 P30542 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CCNT1 O60563 7/20 0.41
CDK1 P06493 7/20 0.41
CCNB1 P14635 7/20 0.41
CCNA2 P20248 7/20 0.41
CDK2 P24941 7/20 0.41
CDK7 P50613 7/20 0.41
CDK9 P50750 7/20 0.41
CCNH P51946 7/20 0.41
CCNA1 P78396 6/20 0.41
LCK P06239 2/20 0.41
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2399934 0.90 MEN1 (0.53) KDRADORA3ADORA2AADORA1MEN1
SCHEMBL2397208 0.84 PIK3CD (0.49) KDRCCNT1CDK1CCNB1CCNA2
SCHEMBL2395328 0.81 KDR (0.49) KDRADORA3ADORA2AADORA1MEN1
SCHEMBL1891863 0.80 KDR (0.41) KDRADORA3ADORA2AADORA1MEN1
SCHEMBL2396335 0.79 PIK3CD (0.57) KDRMEN1KMT2ACCNT1CDK1
SCHEMBL2397578 0.79 CDK2 (0.51) KDRADORA3ADORA2AADORA1MEN1
SCHEMBL2395910 0.78 MEN1 (0.60) MEN1KMT2ACCNT1CDK1CCNB1
SCHEMBL2398032 0.78 PIK3CD (0.47) MEN1KMT2ACCNT1CDK1CCNB1
SCHEMBL2398117 0.78 PIK3CD (0.50) MEN1KMT2ACCNT1CDK1CCNB1
SCHEMBL2398099 0.78 MEN1 (0.45) KDRMEN1KMT2ACCNT1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 KDR 853/4885ADORA3 723/4885ADORA2A 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.